Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00421343 · ClinicalTrials.gov registry record · Phase 3

Secondary Prevention of Osteoporosis

A Phase 3 study of Osteoporosis, sponsored by Hebrew SeniorLife.

Completed
Registry status
Phase 3
Development phase
29
Enrollment target
1
Study location

NCT00421343 is a Phase 3 study of Osteoporosis that has completed, run by Hebrew SeniorLife. The registered enrollment target is 29 participants, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00421343, a Phase 3 study of Osteoporosis, has completed, sponsored by Hebrew SeniorLife.

COMPLETED
Registry status
Phase 3
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.

Conditions Studied

Interventions

  • DRUG alendronate with cholecalciferol
  • DRUG calcium carbonate with cholecalciferol
  • BEHAVIORAL Falls prevention measures

Study Locations (1)

Massachusetts

  • Hebrew SeniorLife - Boston

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2007-02
Est. Completion 2008-06
Phase Phase 3

Sponsor

Hebrew SeniorLife

32 total trials

What the Registry Record Tells You About NCT00421343

The ClinicalTrials.gov registry entry for NCT00421343 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (98% lower). The listed sponsor is Hebrew SeniorLife, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 3 interventions - of which alendronate with cholecalciferol is the first listed.

NCT00421343 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00421343 about?

NCT00421343 is a clinical study titled "Secondary Prevention of Osteoporosis". The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.

What is the current status of trial NCT00421343?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2007-02. Estimated completion is 2008-06.

What conditions does trial NCT00421343 study?

This clinical trial studies the following conditions: Osteoporosis.

What interventions are being tested in trial NCT00421343?

The interventions under investigation include: alendronate with cholecalciferol (DRUG), calcium carbonate with cholecalciferol (DRUG), Falls prevention measures (BEHAVIORAL).

Who is sponsoring clinical trial NCT00421343?

This trial is sponsored by Hebrew SeniorLife, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00421343 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoporosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.